https://www.marketscreener.com/quote/stock/NEUROSENSE-THERAPEUTICS-L-130483704/news/NeuroSense-to-Report-Phase-2b-ALS-Topline-Primary-Safety-and-Tolerability-and-Secondary-Clinical-Eff-45503927/?utm_source=telegram&utm_medium=social&utm_campaign=share